Search canonical names and aliases, then narrow by your evidence and route boundary.
Education and decision support. This release does not generate doses, injection instructions, cycles, diagnoses, prescriptions, or vendor pathways.
A well-characterized GLP-1 therapy with product-specific FDA indications and substantial human evidence.
Visible for broad education until a goal is selected.
FDA approved for defined indications.
An approved GHRF analog whose labeled indication is substantially narrower than common wellness marketing suggests.
Visible for broad education until a goal is selected.
FDA approved for a narrow indication.
A dual GIP/GLP-1 therapy with product-specific FDA indications and substantial human evidence.
Visible for broad education until a goal is selected.
FDA approved for defined indications.
A topical copper peptide with early human skin data; it should not be conflated with injectable GHK-Cu.
Visible for broad education until a goal is selected.
Cosmetic use is not an FDA-approved drug indication.
A heavily marketed recovery compound whose consumer use is far ahead of the available human safety evidence.
Visible for broad education until a goal is selected.
Not FDA approved; no consumer protocol is provided.
A research-market recovery compound with no established consumer indication and a substantial human-data gap.
Visible for broad education until a goal is selected.
Not FDA approved; no consumer protocol is provided.